Oncology

Our oncology portfolio provides cancer patients with a broad range of therapies and practical solutions for the treatment of cancer and hematology. These include:*

• Afinitor (everolimus) for patients with advanced renal cell carcinoma (kidney cancer), whose disease has progressed on or after treatment with VEGF-targeted therapy
• Exjade (deferasirox) for the removal of excess iron due to blood transfusions
• Femara (letrozole) for early-stage or advanced breast cancer in postmenopausal women
• Gleevec/Glivec (imatinib mesylate/imatinib) for certain forms of: chronic myeloid leukemia, acute lymphoblastic leukemia, and gastrointestinal stromal tumors
• Proleukin (aldesleukin) for metastatic renal cell carcinoma and metastatic melanoma
• Sandostatin LAR & Sandostatin SC (octreotide acetate for injectable suspension & octreotide acetate) for acromegaly and symptoms associated with certain gastroenteropancreatic neuroendocrine tumors (carcinoid and VIPomas)
• Tasigna (nilotinib) for certain forms of chronic myeloid leukemia in patients resistant or intolerant to prior treatment including Gleevec/Glivec
• Zometa (zoledronic acid) for prevention of skeletal related events in patients with bone metastases from solid tumors and multiple myeloma, as well as the treatment of hypercalcemia of malignancy.

Visit the Novartis Oncology Websites:

Visit the Novartis Oncology Global website

Visit the Novartis Oncology US website

 

*Not all indications are available in all countries.